Benli Technology announced that its A4, A5, and A2 workshops and production lines for the active pharmaceutical ingredient norfloxacin have passed the GMP compliance inspection by the Zhejiang Medical Products Administration. This inspection confirms that the relevant facilities meet the requirements of Good Manufacturing Practice for pharmaceutical products, laying the foundation for the commercial production and supply of norfloxacin. In the first quarter of 2026, Benli Technology achieved revenue of 162 million yuan and net profit attributable to the parent company of 10.59 million yuan.
Zhejiang Benli Technology Co. Ltd.Passing GMP compliance inspection enables commercial production of norfloxacin.